Quarterly report · Q3
3353.TEDINET S100SM34
Period2023-03-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥28.8bn | 2023-03-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2023-03-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥706m | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-03-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥888m | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2023-03-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥998m | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥812m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥597m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥847m | 2023-03-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥623m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥32.8bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.0bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥19.4bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.4bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.4bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.8bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥216.2 | 2023-03-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.93 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥159 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.34 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-11-30 | −¥670m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-11-30 | −¥544m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥17.7bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥1.3bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥160m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥5.7bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥5.1bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥666m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-11-30 | ¥136m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥3m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-11-30 | ¥99m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-11-30 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-11-30 | ¥28.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-11-30 | ¥670m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-11-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥557m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥35m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥2.2bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥742m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥29m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥142m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-11-30 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-11-30 | ¥25.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥744m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-11-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 370
| Item | Context | Value | Unit |
|---|---|---|---|
| Short term loans payable | Prior1YearInstant | 170000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 2810000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 2694980000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 2397760000 | JPY |
| Income taxes payable | Prior1YearInstant | 189206000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 330602000 | JPY |
| Provision for bonuses | Prior1YearInstant | 222824000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 28127000 | JPY |
| Other cl | Prior1YearInstant | 738919000 | JPY |
| Other cl | CurrentQuarterInstant | 1401916000 | JPY |
| Current liabilities | Prior1YearInstant | 7454768000 | JPY |
| Current liabilities | CurrentQuarterInstant | 12197936000 | JPY |
| Long term loans payable | Prior1YearInstant | 6062910000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 5541000000 | JPY |
| Lease obligations ncl | Prior1YearInstant | 189717000 | JPY |
| Lease obligations ncl | CurrentQuarterInstant | 171710000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 802137000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 1021901000 | JPY |
| Other ncl | Prior1YearInstant | 388400000 | JPY |
| Other ncl | CurrentQuarterInstant | 429416000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 7443165000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 7164028000 | JPY |
| Liabilities | Prior1YearInstant | 14897934000 | JPY |
| Liabilities | CurrentQuarterInstant | 19361965000 | JPY |
| Capital stock | Prior1YearInstant | 917000000 | JPY |
| Capital stock | CurrentQuarterInstant | 917000000 | JPY |
| Capital surplus | Prior1YearInstant | 1081272000 | JPY |
| Capital surplus | CurrentQuarterInstant | 1081749000 | JPY |
| Retained earnings | Prior1YearInstant | 10557964000 | JPY |
| Retained earnings | CurrentQuarterInstant | 11204378000 | JPY |
| Treasury stock | Prior1YearInstant | -539830000 | JPY |
| Treasury stock | CurrentQuarterInstant | -537933000 | JPY |
| Shareholders equity | Prior1YearInstant | 12016406000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 12665194000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 27858000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 144040000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 5068000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 1267000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 32926000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 145307000 | JPY |
| Non controlling interests | Prior1YearInstant | 558509000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 593062000 | JPY |
| Net assets | Prior1YearInstant | 12607842000 | JPY |
| Net assets | CurrentQuarterInstant | 13403564000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 27505776000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 32765530000 | JPY |
| Net sales | Prior1YTDDuration | 25427609000 | JPY |
| Net sales | CurrentYTDDuration | 28769800000 | JPY |
| Cost of sales | Prior1YTDDuration | 23002205000 | JPY |
| Cost of sales | CurrentYTDDuration | 25603354000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |